A number of drug candidates and experimental therapies, including autologous EBV-specific CTL [83], IL-2-activated NK cells [84], anti-CTLA-4 antibody [85], rituximab and IL-2 in combination [86], GM-CSF and IL-2 in combination [87], low-dose IL-2 [88], and the combination of CD13/CD19-bispecific antibody, CD28 specific antibody, and autologous T cells [89], were evaluated using scid-hu PBL mice with EBV-positive LPD. The gene discussed is IL2; the disease is disseminated peritoneal leiomyomatosis.